Integrative preclinical strategy for pharmacokinetic profiling and candidate selection of 3-hydroxypropanamidines: a promising antimalarial class

TKK130 was identified as the most favorable compound of the novel antimalarial 3-hydroxypropanamidines because of its encouraging pharmacokinetic profile, combined with its excellent in vivo efficacy and lack of observed toxicity in mice. TKK130 is a promising candidate for further preclinical and clinical development.